Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. - Wikidata - awgldk - TriplyDB

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

http://www.wikidata.org/entity/Q45097041

about

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*The renaissance of fixed dose combinations: Combivir Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy Abacavir/lamivudine combination in the treatment of HIV: a review.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis Pharmacogenetics of drug hypersensitivity.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Zidovudine and Lamivudine for HIV Infection.Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia.Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.Individualization of antiretroviral therapy.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Antiretroviral treatment of HIV infection: Swedish recommendations 2007.Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.Pharmacogenetic information derived from analysis of HLA alleles.Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.Efavirenz: a decade of clinical experience in the treatment of HIV.Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Successful translation of pharmacogenetics into the clinic: the abacavir example.HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.Causes and consequences of incomplete HIV RNA suppression in clinical trials.

P2860

Q27015850-A16C0E79-7312-4838-A7E0-A3FF555EEC1F Q28279752-88B49712-7DCD-43B1-B8E5-242753658D28 Q28471623-0C65E056-D467-4721-8F0B-6297E6595A6E Q28473296-329FD6BD-CFC5-4285-A466-9D2B4E797381 Q28547109-7401A40F-0E77-45AF-8596-8A8B27873F7F Q33258171-5854E7BE-6EFB-472F-85CC-35ADE03CFAA3 Q33565604-3B040E8E-C254-47F5-9DB1-D9D2D1E9CE9C Q33715435-66E43ABA-F9F0-4812-B2FD-0ADB535111FB Q33988153-7EE590D5-4BC6-4571-9939-7420F47DB4B3 Q34118186-6828CD11-A6E3-431E-B05F-DD90A3D2D3E3 Q34134900-910927CD-5085-434C-8835-D6A46D9E09E8 Q34194561-3E17E305-1392-4BA6-9246-B79F47F4870C Q34499007-F3EE5FFF-5725-44CD-A70B-705B59980168 Q34503452-52B34F39-1DA0-464F-905D-3B26EA0584FA Q34713094-6BFA5BFE-F37E-41B2-97BE-E3DE84C82853 Q35214141-F6A74F71-C2C7-45FA-B195-C2ECC2772B9B Q35233168-747624B6-0F99-4A39-898D-77C8920098FB Q35959086-D6E6545B-C9F7-49D3-A75C-BF192678CE5E Q36156655-05C7D43E-B964-4D7C-BDD3-271B29A1D0A0 Q36198650-38F63C21-1A95-4995-A503-55639DA46806 Q36276597-9E97A60D-78DF-4DD6-9A85-AB10F0505899 Q36322100-51F16656-E12C-426A-9469-A8C428F6EA99 Q36343668-B33AC237-6A9E-4D59-B488-897333D510E2 Q36441423-F0B26340-4E9A-4B41-A3A4-AE901A7EE38B Q36653838-94676917-D988-42F4-86E3-81FAA7315570 Q36675417-F19E7FF9-31FE-492B-BA8B-256E733CD8D3 Q36688943-2662EEBD-0685-4114-82F7-159AB75F4496 Q36718901-17AEB858-0A1D-4354-B976-DCEFBC5A35D6 Q36852859-627C2A09-3646-4E8E-A045-C4CCE1996510 Q36919659-37082F0E-8376-4BA1-BEAD-879E17261109 Q37107177-4A0B27C1-361F-4043-A436-D88342CB84FC Q37120841-B25D3D4F-8EB9-4000-BAE1-B3E38D74C4D9 Q37228748-13F8820F-C68C-4066-A86D-39C2FDE74EE6 Q37328870-7CAAC702-B3CE-4D65-B488-392F719DBA09 Q37365825-1F06182C-8025-4523-9D35-B720983AA421 Q37383949-FFF5498C-C27C-477C-9853-BD1C00C97065 Q37389496-8B0EA31B-D5CA-4114-9A86-FFCB855939A8 Q37436365-963435C8-0767-44F4-A29D-7C0EE6379B57 Q37514235-60243191-38C8-4836-8F70-1B356C5BF0EE Q37631282-E97601D6-F197-4E5E-8E01-04B7505D1279

P2860

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

http://www.wikidata.org/entity/Q45097041

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@en

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@nl

type

label

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@en

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@nl

prefLabel

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@en

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@nl

P1433

Q45097041-80929F71-50BB-46C9-92E5-C2BB9CB25FCC

P1476

Q45097041-B818C8AC-18FB-4E65-A5F2-680D3FB6D85F

P2093

Q45097041-0B59002C-09F5-49E4-BF1C-F4B5511DA936

Q45097041-4E2C964B-83C3-4753-AC52-EED2E6A06450

Q45097041-69A5BE15-CB49-45B6-8C89-C8F348E30AB9

Q45097041-6FC997E9-0C9F-4A12-8858-4C57F4461983

Q45097041-79D3424B-343F-45B6-8EE2-B5CA58934933

Q45097041-7ADD06EF-259C-4F48-B05C-6C56EC7479EC

Q45097041-979810FD-E047-4BA0-B1F6-0576EE934873

Q45097041-A2C7ABA9-8884-4849-85C2-3A8F0B0883BB

Q45097041-A5E35C71-2ED5-41C4-9A7C-59AB4BC6CDAA

Q45097041-AE2B4DA3-58BB-4E14-A881-684CBC71A5B6

P304

Q45097041-4F077296-C168-495B-89E1-8ECD72DC4E3D

P31

Q45097041-49EAD30E-9FAE-4633-9F97-6DAA14FA23AF

P356

Q45097041-7BE03925-6607-45CB-B6A6-A40EFA7CCD05

P407

Q45097041-23146D19-0EFE-4040-A1B7-726C5A75120A

P433

Q45097041-9C7B430E-FC2E-4725-89EE-74025479E1DF

P478

Q45097041-D8CC1ABE-4132-4736-8E84-C3EEA5132338

P577

Q45097041-4475A6D5-C89E-49DC-8208-0314DA42C629

P5875

Q45097041-1DF6A636-909B-4283-BAFD-13F891EB29B5

P698

Q45097041-88BA86DB-3511-48C4-9F99-1E9C865364CB

P356

P1433

Clinical Infectious Diseases

P1476

Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.

@en

P2093

CNA30024 Study Team

http://www.w3.org/2001/XMLSchema#string

Carlos Beltran Buendia

http://www.w3.org/2001/XMLSchema#string

Cynthia H Brothers

http://www.w3.org/2001/XMLSchema#string

E Randall Lanier

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Eugenio Teofilo

http://www.w3.org/2001/XMLSchema#string

Gisela Herrera

http://www.w3.org/2001/XMLSchema#string

J David Brand

http://www.w3.org/2001/XMLSchema#string

Jaime Hernandez

http://www.w3.org/2001/XMLSchema#string

Jan Gerstoft

http://www.w3.org/2001/XMLSchema#string

P304

1038-1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/424009

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8242663

http://www.w3.org/2001/XMLSchema#string

P698

15472858

http://www.w3.org/2001/XMLSchema#string